Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 7Hematologic Neoplasms 4Waldenstrom Macroglobulinemia 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, B-Cell 2Vascular Diseases 1Recurrence 1Paraproteinemias 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasms 1Mature B-cell Neoplasms 1Lymphoproliferative Disorders 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphatic Diseases 1Leukemia, Lymphoid 1Leukemia 1Immunoproliferative Disorders 1Immune System Diseases 1Hemostatic Disorders 1Hemorrhagic Disorders 1Dendritic Cell Sarcoma, Interdigitating 1Cardiovascular Diseases 1Blood Protein Disorders 1

Interventions

Rituximab 161Cyclophosphamide 142fludarabine phosphate 89Peripheral Blood Stem Cell Transplantation 81Filgrastim 59Mycophenolic Acid 58Whole-Body Irradiation 53Cyclosporine 53Radiotherapy 52Lenalidomide 47Busulfan 45Tacrolimus 44Etoposide 43Antilymphocyte Serum 41Melphalan 37Methotrexate 31fludarabine 30Bortezomib 30Prednisone 28Bendamustine Hydrochloride 28Cytarabine 24Cord Blood Stem Cell Transplantation 23obinutuzumab 22Vincristine 22Methylprednisolone 21Flow Cytometry 21ibrutinib 19venetoclax 18sargramostim 17Granulocyte Colony-Stimulating Factor 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, B-Cell, Marginal Zone × ARQ531 × Clear all
NCT07583810 2026-05-15

Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma

City of Hope Medical Center

Phase 2 Not yet recruiting
35 enrolled
Lymphoid

Lymphoma, Lymphoma, B-Cell, Marginal Zone

NCT03162536 2025-09-08

ARQ 531-101

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1/2 Active not recruiting
190 enrolled
LymphoidOther hematologic neoplasmPlasma cellSarcoma

Blood Protein Disorders, Cardiovascular Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Lymphoid, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Recurrence, Vascular Diseases, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Hemostatic Disorders, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡